# MAY 1 2 2005 Section E

510(k) Summary of Safety and Effectiveness

For

# VARIANT™"nbs Sickle Cell Program

Sec. E - 510(k) Summary of Safety and Effectiveness

# 510(k) Summary of Safety and Effectiveness

# Submitter

Address:

Bio-Rad Laboratories, Inc. Clinical Systems Division 4000 Alfred Nobel Drive   
Hercules, CA 94547 U.S.A. (510) 724-7000   
(510) 741-6471

Phone: Facsimile:

# Contact Person

William Gary Gustafson   
Regulatory Affairs Representative   
(510) 741-6114   
(510) 741-6471   
bill_gustafson@bio-rad.com

Phone: Facsimile: E-Mail:

Preparation Date

March 17, 2005

# New device Name

Trade Name: Common Name: Classification Name:

Bio-Rad VARIANT™Mnbs Sickle Cell Program Hemoglobin F, A, S, D, C and E Determination by HPLC Abnormal Hemoglobin Quantitation (21 CFR 864.7415)

# Predicate Device Name

Trade Name: Classification Name: Applicant: 510(k) Number:

Bio-Rad VARIANTTM Sickle Cell Short Program   
Abnormal Hemoglobin Quantitation (21 CFR 864.7415) Bio-Rad Laboratories, Inc.   
K924813

# Indications for Use Statement and Intended Uses

The Bio-Rad VARIANTnbs Sickle Cell Program is intended as a qualitative screen for the presence of hemoglobins F, A, S, D, C and E in eluates of neonatal blood collected on filter paper by high performance liquid chromatography (HPLC).

The Bio-Rad VARIANTnbs Sickle Cell Program is intended for Professional Use Only. For In Vitro Diagnostic Use.

The Bio-Rad VARIANTnbs Sickle Cell Program is for use only with the Bio-Rad VARIANTnbs Newborn Screening System.

# Sec. E - 510(k) Summary of Safety and Effectiveness

# New Device Description

The VARIANTnbs Newborn Screening System is a High Performance Liquid Chromatography (HPLC) system consisting of an auto sampler for microwell plates (VARIANTnbs Neonatal Auto Sampler) and a chromatography station (VARIANTnbs Neonatal Chromatography Station). The VARIANTnbs Sickle Cell Program is a reagent kit that includes an analytical cartridge containing cation exchange resin and two (2) buffers for establishing a gradient. The Genetic Data Management (GDM) software is designed to execute the VARIANTnbs Sickle Cell Program on the VARIANTnbs Newborn Screening System for the purposes of qualitatively screening for the presence of normal hemoglobins F and A and abnormal hemoglobins S, D, C and E in eluates of discs punched from neonatal heel stick blood collected on filter prlu p re patowe plats with h l pape i ip, collected in a sample loop and then injected into the flow path of the chromatography module. The hemoglobins of interest are retained on the analytical cartridge in the presence of Elution Buffer . The ionic strength is subsequently raised by adding increasing amounts of Elution Buffer 2. The preprogrammed gradient is designed to have the hemoglobins of interest elute from the cartridge with retention times that fall within pre-determined windows characteristic of known hemoglobins. Eluted hemoglobins are detected with a dual-wavelength filter photometer which monitors hemoglobin absorbance at 415 nm and corrects for any gradient induced absorbance changes at 690 nm. Processed dat iuu a pri rer hat nassentn, aten te nalyss, peak table containing observed peak name(s), retention time(s), peak height(s), peak area(s), and relative area percent(s), 4) total chromatogram area, 5) chromatogram and 6) any error message(s).Also reported is an optional "pattern assignment" based upon "pattern rules" derived from literature.

# Comparison with Predicate Device

<table><tr><td colspan="3" rowspan="1">Summary of Technological Characteristic Similarities to Predicate Device</td></tr><tr><td colspan="1" rowspan="1">Features</td><td colspan="1" rowspan="1">New Device:Bio-Rad VARIANT™nbs Sickle CellProgram</td><td colspan="1" rowspan="1">Predicate Device:Bio-Rad VARIANTTM Sickle Cell ShortProgram(K#924813)</td></tr><tr><td colspan="1" rowspan="3">Intended Use</td><td colspan="1" rowspan="1">The Bio-Rad VARIANTnbs Sickle CellProgram is intended as a qualitativescreen for the presence of hemoglobins F,A, S, D, C and E in eluates of neonatalblood collected on filter paper by highperformance liquid chromatography(HPLC).</td><td colspan="1" rowspan="1">The VARIANT Sickle Cell ShortProgram is designed as a qualitativescreen for the presence of hemoglobins F,A, S, D, C and E in eluates of neonatalblood collected on filter paper by highperformance liquid chromatography.</td></tr><tr><td colspan="1" rowspan="1">For In Vitro Diagnostic Use.</td><td colspan="1" rowspan="1">For In Vitro Diagnostic Use.</td></tr><tr><td colspan="1" rowspan="1">For Professional Use Only.</td><td colspan="1" rowspan="1">For Professional Use Only.</td></tr><tr><td colspan="1" rowspan="1">Target Population</td><td colspan="1" rowspan="1">Neonates.</td><td colspan="1" rowspan="1">Neonates.</td></tr><tr><td colspan="1" rowspan="1">Design - Assay principle</td><td colspan="1" rowspan="1">Cation exchange high performance liquidchromatography.</td><td colspan="1" rowspan="1">Cation exchange high performance liquidchromatography.</td></tr><tr><td colspan="1" rowspan="1">Design - Assay Detection</td><td colspan="1" rowspan="1">Heme absorbance at 415 nm withbackground correction at 650 nm.</td><td colspan="1" rowspan="1">Heme absorbance at 415 nm withbackground correction at 650 nm.</td></tr><tr><td colspan="1" rowspan="1">Design - AnalytesIdentified</td><td colspan="1" rowspan="1">Six retention time windows forhemoglobins F, A, E, D, S and C.</td><td colspan="1" rowspan="1">Six retention time windows forhemoglobins F, A, E, D, S and C.</td></tr><tr><td colspan="1" rowspan="1">Design - Sample Type</td><td colspan="1" rowspan="1">Neonatal dried blood spots on filter papercollection cards.</td><td colspan="1" rowspan="1">Neonatal dried blood spots on filter papercollection cards.</td></tr><tr><td colspan="1" rowspan="1">Design - Punched Disc</td><td colspan="1" rowspan="1">One 1/8" disc.</td><td colspan="1" rowspan="1">One 1/8" disc.</td></tr><tr><td colspan="1" rowspan="1">Features</td><td colspan="1" rowspan="1">New Device:Bio-Rad VARIANTTMnbs Sickle CellProgram</td><td colspan="1" rowspan="1">Predicate Device:Bio-Rad VARIANTTM Sickle Cell ShortProgram(K#924813)</td></tr><tr><td></td><td colspan="1" rowspan="2">Accepts manual worklists.</td><td colspan="1" rowspan="2">Accepts manual worklists.</td></tr><tr><td colspan="1" rowspan="1">Design - Manual Worklists</td></tr><tr><td colspan="1" rowspan="1">Materials - Components</td><td colspan="1" rowspan="1">Elution Buffer 1. Elution Buffer 2.Wash Solution. Analytical Cartridge.Lyophilized Whole Blood Primer.Lyophilized Retention Time Marker 1(FAES). Lyophilized Retention TimeMarker 2 (FADC).</td><td colspan="1" rowspan="1">Elution Buffer 1. Elution Buffer 2.Wash Solution. Analytical Cartridge.Lyophilized Whole Blood Primer.Lyophilized Retention Time Marker 1(FAES). Lyophilized Retention TimeMarker 2 (FADC).</td></tr><tr><td colspan="1" rowspan="1">Performance - Precision</td><td colspan="1" rowspan="1">Peak retention time precision is &lt;1% forall hemoglobin peaks.</td><td colspan="1" rowspan="1">Peak retention time precision is &lt;1% forall hemoglobin peaks.</td></tr><tr><td colspan="1" rowspan="1">Compatibility withEnvironment</td><td colspan="1" rowspan="1">U.S. FCC EMI and E.U. EMC standardcompliant.</td><td colspan="1" rowspan="1">U.S. FCC EMI and E.U. EMC standardcompliant.</td></tr><tr><td colspan="1" rowspan="1">Human Factors</td><td colspan="1" rowspan="1">For in vitro diagnostic use. Forprofessional use only.</td><td colspan="1" rowspan="1">For in vitro diagnostic use. Forprofessional use only.</td></tr><tr><td></td><td colspan="1" rowspan="2">Auto-switching 1 10 V and 220 V.</td><td colspan="1" rowspan="2">110 V and 220 V models.</td></tr><tr><td colspan="1" rowspan="1">Energy Used</td></tr><tr><td colspan="1" rowspan="1">Chemical Safety</td><td colspan="1" rowspan="1">Sodium azide concentration &lt;0.05%.Gentamicin Sulfate concentration &lt;0.1%.Tobramycin concentration &lt;0.1%.Warnings provided in labeling asrequired, including State of CaliforniaProposition 65 Warning.</td><td colspan="1" rowspan="1">Sodium azide concentration &lt;0.05%.Gentamicin Sulfate concentration &lt;0.1%.Tobramycin concentration &lt;0.1%.Warnings provided in labeling asrequired, including State of CaliforniaProposition 65 Warning.</td></tr><tr><td colspan="1" rowspan="1">Electrical, Mechanical andThermal Safety</td><td colspan="1" rowspan="1">System certification to US and Canadianproduct safety standards and EU lowvoltage safety standards.</td><td colspan="1" rowspan="1">System certification to US and Canadianproduct safety standards and EU lowvoltage safety standards.</td></tr><tr><td colspan="1" rowspan="2">Standards Met</td><td colspan="1" rowspan="2">•  EN375:2002EN591:2001EN980:2003EN1658:1996EN13485:2003EN13640:2002EN14971:2001EN61010-1:2001EN61010-2-101:2002EN61326:2001</td><td colspan="1" rowspan="2">EN375:2002EN591:2001EN980:2003EN1658:1996EN13485:2003EN13640:2002EN14971:2001EN61010-1:2001EN61010-2-101:2002EN61326:2001</td></tr><tr></tr></table>

<table><tr><td colspan="3" rowspan="1">Summary of Technological Characteristic Differences in Comparison to Predicate Device</td></tr><tr><td colspan="1" rowspan="1">Features</td><td colspan="1" rowspan="1">New Device:Bio-Rad VARIANT™Mnbs Sickle CellProgram</td><td colspan="1" rowspan="1">Predicate Device:Bio-Rad VARIANTTM Sickle Cell ShortProgram(K#924813)</td></tr><tr><td colspan="1" rowspan="1">Design - SystemConfiguration</td><td colspan="1" rowspan="1">Separate chromatography and autosampler modules and separate PCworkstation with software.</td><td colspan="1" rowspan="1">Single integrated unit withchromatography, auto sampler andsoftware functionalities.</td></tr><tr><td colspan="1" rowspan="1">Design - Media</td><td colspan="1" rowspan="1">CD-ROM.</td><td colspan="1" rowspan="1">ROM Card.</td></tr><tr><td colspan="1" rowspan="1">Features</td><td colspan="1" rowspan="1">New Device:Bio-Rad VARIANT™nbs Sickle CellProgram</td><td colspan="1" rowspan="1">Predicate Device:Bio-Rad VARIANTTM Sickle Cell ShortProgram(K#924813)</td></tr><tr><td colspan="1" rowspan="1">Design - Container, ElutionVolume, ReconstitutionVolume, Sample Loop,Column loading</td><td colspan="1" rowspan="1">Plastic 96 microwell plate. 250 μLsample elution volume. 500 pL primerand retention time marker reconstitutionvolume. 10 μL sample loop. Columnloading is 1/25 of eluted sample volumeand 1/50 of reconstituted material.</td><td colspan="1" rowspan="1">Plastic sample vial. 500 μL sampleelution volume. 1000 μL primer andretention time marker reconstitutionvolume. 20 pL sample loop. Columnloading is 1/25 of eluted sample volumeand 1/50 of reconstituted material.</td></tr><tr><td colspan="1" rowspan="1">Design - Aspiration ProbeTip, Punched DiscDisposition</td><td colspan="1" rowspan="1">Beveled aspiration probe tip. Dried bloodspot punched disc left in microwell duringsample aspiration.</td><td colspan="1" rowspan="1">Blunt aspiration probe tip. Dried bloodspot punched disc removed before sampleaspiration.</td></tr><tr><td colspan="1" rowspan="1">Design - Additionalretention time windows.</td><td colspan="1" rowspan="1">Seven (7) additional retention timewindows: F1, "Other (1)", "Other (2)",Other (3)", "Other (4)", "Other (5)" and"Other (6)".</td><td colspan="1" rowspan="1">Feature not available.</td></tr><tr><td colspan="1" rowspan="1">Design - AutomatedWorklists</td><td colspan="1" rowspan="1">Accepts automated worklists from spotpunchers.</td><td colspan="1" rowspan="1">Feature not available.</td></tr><tr><td colspan="1" rowspan="1">Design - Pattern Assignment</td><td colspan="1" rowspan="1">Optional pattern assignment feature usespattern rules derived from literature.</td><td colspan="1" rowspan="1">Feature not available.</td></tr><tr><td colspan="1" rowspan="1">Performance - VariantsLimit of Detection</td><td colspan="1" rowspan="1">The limit of detection for S, D, C and E is1% of the total area of the sample whenthe total area is 1.5 millionmicrovolt·second.</td><td colspan="1" rowspan="1">Limit of detection for hemoglobins S, D,C and E is 1% of the total area when thetotal area of the sample is 1.0 millionmicrovolt·second.</td></tr><tr><td colspan="1" rowspan="1">Performance - Guideline forInterpretation of Results</td><td colspan="1" rowspan="1">Total area must be between 900,000 to6.3 million microvolt·second.</td><td colspan="1" rowspan="1">Total area should range from 1,000,000-3,000,000 microvolt·second.</td></tr><tr><td colspan="1" rowspan="1">Performance - Total AreaLimit of Detection</td><td colspan="1" rowspan="1">900,000 microvolt-second.</td><td colspan="1" rowspan="1">Not addressed in instruction manual.</td></tr><tr><td colspan="1" rowspan="1">Performance - Bilirubininterference</td><td colspan="1" rowspan="1">Bilirubin up to 20 mg/dL does notinterfere.</td><td colspan="1" rowspan="1">Not addressed in instruction manual.</td></tr><tr><td colspan="1" rowspan="1">Performance - Triglycerideinterference</td><td colspan="1" rowspan="1">Triglyceride up to 6000 mg/dL does notinterfere.</td><td colspan="1" rowspan="1">Not addressed in instruction manual.</td></tr><tr><td colspan="1" rowspan="1">Performance - Eluatestability</td><td colspan="1" rowspan="1">Eluates are stable for 48 hrs on the cooledauto sampler and at 2-8 °C and stable for24 hrs at 15-30 °C.</td><td colspan="1" rowspan="1">Eluates are stable for 24 hrs at 2-8 °C.</td></tr><tr><td colspan="1" rowspan="1">Guidances Met</td><td colspan="1" rowspan="1">FDA 2002 - General Principles ofSoftware Validation; Final Guidancefor Industry and FDA Staff.FDA 1999 - Guidance for Off-the-Shelf Software Use in MedicalDevices; Final.FDA 1998 - Guidance for the Contentof Premarket Submissions forSoftware Contained in MedicalDevices; Final.FDA 2003 - Device Advice; Contentof a 510(k)</td><td colspan="1" rowspan="1">Not addressed.</td></tr><tr><td colspan="1" rowspan="1">Standards Met</td><td colspan="1" rowspan="1">NCCLS EP-05A 1999.NCCLS EP-05A2 2004.</td><td colspan="1" rowspan="1">Not addressed.</td></tr></table>

# Sec. E - 510(k) Summary of Safety and Effectiveness

# Testing to Establish Equivalence

# Correlation

Method correlation between predicate device and Bio-Rad VARIANTTMnbs Sickle Cell Program new device was evaluated using 1025 samples prepared from neonatal dried blood spot collection cards. The results are presented in the following table:

<table><tr><td rowspan=1 colspan=5>Hemoglobin Identification Correlation Summary</td></tr><tr><td rowspan=2 colspan=1>−</td><td rowspan=2 colspan=1>Number ofSamples</td><td rowspan=1 colspan=1>Predicate Device</td><td rowspan=1 colspan=2>New device</td></tr><tr><td rowspan=1 colspan=1>F, A, E, D, S and (or) C Identified</td><td rowspan=1 colspan=1>Agree</td><td rowspan=1 colspan=1>Disagree</td></tr><tr><td rowspan=9 colspan=1></td><td rowspan=1 colspan=1>591</td><td rowspan=1 colspan=1>FA</td><td rowspan=1 colspan=1>590</td><td rowspan=1 colspan=1>1 (FAS)</td></tr><tr><td rowspan=1 colspan=1>52</td><td rowspan=1 colspan=1>FAE</td><td rowspan=1 colspan=1>52</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>38</td><td rowspan=1 colspan=1>FAD</td><td rowspan=1 colspan=1>37</td><td rowspan=1 colspan=1>1 (FADC)</td></tr><tr><td rowspan=1 colspan=1>247</td><td rowspan=1 colspan=1>FAS</td><td rowspan=1 colspan=1>247</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>FAC</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>FSC</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>FC</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>FE</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=3>Total         1025</td><td rowspan=1 colspan=2>1023                   2</td></tr></table>

# Precision

The Bio-Rad VARIANTTMnbs Sickle Cell Program new device retention time precision protocol was based on NCCLS Protocol EP5-A (Vol. 19, No. 2) and EP5-A2 (Vol. 24, No. 25). Two analytical runs were performed per day on 20 days for a total of 40 runs on each of 3 separate systems. Each run included 4 replicates of two retention time positional QC controls. Within-run precision and withindevice precision (formerly total precision) were determined. The reported predicate device retention time precision protocol included the same two retention time positional QC controls, however, the protocol did not conform to NCCLS Protocol EP5-A2 guidelines nor was with-in laboratory (or withindevice) precision reported. The results are presented in the following tables:

<table><tr><td rowspan=1 colspan=9>Retention Time With-in Run Precision Summary</td></tr><tr><td rowspan=2 colspan=1>Device</td><td rowspan=2 colspan=1>Replicates</td><td rowspan=2 colspan=1>Sample</td><td rowspan=1 colspan=6>Retention Time Within-Run Precision (CV %)</td></tr><tr><td rowspan=1 colspan=1>Peak F</td><td rowspan=1 colspan=1>Peak A</td><td rowspan=1 colspan=1>Peak E</td><td rowspan=1 colspan=1>Peak D</td><td rowspan=1 colspan=1>Peak S</td><td rowspan=1 colspan=1>Peak C</td></tr><tr><td rowspan=1 colspan=1>New</td><td rowspan=1 colspan=1>160x3</td><td rowspan=1 colspan=1>QC Control 1</td><td rowspan=1 colspan=1>0.3-0.5</td><td rowspan=1 colspan=1>0.3-0.4</td><td rowspan=1 colspan=1>0.3-0.4</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0.2-0.3</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Predicate</td><td rowspan=1 colspan=1>10x1</td><td rowspan=1 colspan=1>QC Control 1</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>New</td><td rowspan=1 colspan=1>160x3</td><td rowspan=1 colspan=1>QC Control 2</td><td rowspan=1 colspan=1>0.3-0.5</td><td rowspan=1 colspan=1>0.3-0.4</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0.2-0.3</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0.1-0.3</td></tr><tr><td rowspan=1 colspan=1>Predicate</td><td rowspan=1 colspan=1>10x1</td><td rowspan=1 colspan=1>QC Control 2</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0.3</td></tr></table>

# Sec. E - 510(k) Summary of Safety and Effectiveness

<table><tr><td rowspan=1 colspan=9>Retention Time With-in Device Precision (Formerly Total Precision)</td></tr><tr><td rowspan=2 colspan=1>Device</td><td rowspan=2 colspan=1>Replicates</td><td rowspan=2 colspan=1>Sample</td><td rowspan=1 colspan=6>Retention Time Within-Device Precision (CV %)</td></tr><tr><td rowspan=1 colspan=1>Peak F</td><td rowspan=1 colspan=1>Peak A</td><td rowspan=1 colspan=1>Peak E</td><td rowspan=1 colspan=1>Peak D</td><td rowspan=1 colspan=1>Peak S</td><td rowspan=1 colspan=1>Peak C</td></tr><tr><td rowspan=1 colspan=1>New</td><td rowspan=1 colspan=1>160x 3</td><td rowspan=1 colspan=1>QC Control I</td><td rowspan=1 colspan=1>0.3-0.6</td><td rowspan=1 colspan=1>0.4-0.6</td><td rowspan=1 colspan=1>0.4-0.6</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0.5-0.6</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>.Predicate</td><td rowspan=1 colspan=2>Not reported</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td></td><td rowspan=2 colspan=1>160x3</td><td rowspan=2 colspan=1>QC Control 2</td><td rowspan=2 colspan=1>0.3-0.7</td><td rowspan=2 colspan=1>0.4-0.6</td><td rowspan=2 colspan=1></td><td rowspan=2 colspan=1>0.4-0.5</td><td rowspan=2 colspan=1></td><td rowspan=2 colspan=1>0.2-0.3</td></tr><tr><td rowspan=1 colspan=1>New</td></tr><tr><td rowspan=1 colspan=1>Predicate</td><td rowspan=1 colspan=2>Not reported.</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr></table>

# Variant Peak Area Limit of Detection

The Bio-Rad VARIANTrMnbs Sickle Cell Program new device peak area limit of detection for hemoglobin variants (E, D, S and C) was determined using a total of 102 sample measurements bracketing the 1% peak area limit of detection for each variant when the total chromatogram area was 1.5 million microvolt second. The reported predicate device peak area limit of detection was 1% when the total chromatogram area was 1.0 million microvolt·second. The results are presented in the following table:

<table><tr><td rowspan=1 colspan=6>Variant Peak Area Limit of Detection</td></tr><tr><td rowspan=2 colspan=1>Device</td><td rowspan=2 colspan=1>ChromatogramTotal Area(microvolt·second)</td><td rowspan=1 colspan=4>Peak Area% Limit of Detection</td></tr><tr><td rowspan=1 colspan=1>Peak E</td><td rowspan=1 colspan=1>Peak D</td><td rowspan=1 colspan=1>Peak S</td><td rowspan=1 colspan=1>Peak C</td></tr><tr><td rowspan=1 colspan=1>New</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>1%</td><td rowspan=1 colspan=1>1%</td><td rowspan=1 colspan=1>1%</td><td rowspan=1 colspan=1>1%</td></tr><tr><td rowspan=1 colspan=1>Predicate</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>1%</td><td rowspan=1 colspan=1>1%</td><td rowspan=1 colspan=1>1%</td><td rowspan=1 colspan=1>1%</td></tr></table>

# Conclusions

The similarities of the intended use and the general performance characteristics and results of the newly described and evaluated Bio-Rad VARIANTTMnbs Sickle Cell Program new device used with the Bio-Rad VARIANTTMnbs Newborn Screening System with Bio-Rad Genetic Data Management Software for the VARIANTTMnbs Newborn Screening System are nearly identical to logical extensions of those for the cleared predicate device and associated system. Thus, one may conclude based on the new device system use of the same HPLC technology, and the nearly equivalent results obtained from the correlation, precision and variant peak area limit of detection versus the corresponding results obtained with the predicate device system that the new Bio-Rad VARIANTTMnbs Sickle Cell Program system is substantially equivalent to the cleared and currently marketed predicate device system.

# MAY 1 2 2005

Bio-Rad Laboratories   
c/o Dr. Alfredo J. Quattrone   
California Department of Health Services (CA-DHS)   
Food and Drug Branch, MS-7602   
1500 Capitol Avenue   
Sacramento, CA 95814

Re: k051072 Trade/Device Name: Bio-Rad VARIANTTM nbs Sickle Cell Program Regulation Number: 21 CFR 864.7415 Regulation Name: Abnormal hemoglobin assay Regulatory Class: Class II \* Product Code: GKA Dated: April 19, 2005 Received: April 26, 2005

Dear Dr. Quattrone:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or classIII (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

Page 2 -

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0484. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html

Sincerely yours,

fobathBecterh

Robert L. Becker, Jr., MD, PH.D   
Director   
Division of Immunology and Hematology   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and   
Radiological Health

Enclosure

Sec. D - 510(k) Statement of Indications for Use

Statement of Indications for Use

510(k) Number if Known:

K051072

Device Name:

# Bio-Rad VARIANT™"nbs Sickle Cell Program

Indications for Use:

The Bio-Rad VARIANTnbs Sickle Cell Program is intended as a qualitative screen for the presence of hemoglobins F, A, S, D, C and E in eluates of neonatal blood collected on filter paper by high performance liquid chromatography (HPLC).

The Bio-Rad VARIANTnbs Sickle Cell Program is intended for Professional Use Only. For In Vitro Diagnostic Use.

The Bio-Rad VARIANTnbs Sickle Cell Program is for use only with the Bio-Rad VARIANTnbs Newborn Screening System.

![](images/e12a0bdea286f4f561b3de91f208905fe82368cab57a5ceca3592c2ef3ad014f.jpg)

(Patiption U Subpat D AND/OR (ver-The-Cousuepust)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE

)   
DivisiorSign-off   
Office of In Vitro Diagnostic Device Page 1 of 1   
Evaluation and Safety K051072   
510(k)

Bio-Rad Laboratories, Inc. Bio-Rad VARIANTnbs Sickle Cell Program 51O(k)